Looking into DexCom (DXCM). The stock has dropped significantly but if you do a full analysis (researching both its competitors and running the DCF model) there's still about 12% upside in a base case, and 20% upside based on current cash flow (only about .9% in a bear case). There are obviously more factors that go into it, but basically: based on growth trends in revenue as well as consistent margins, competitive positioning against its main competitor (Abbott laboratories) and its potential for expansion to new markets the stock has upside. Disclosure: I do have a position in DexCom however after completing my research I'm looking to add more.